Chronic lymphocytic leukemia (CLL) is largely a disease of older individuals. As the incidence rate rises with age, the prevalence and mortality of CLL are likely to increase further due to demographic changes in society.
Moreover, the proportion of younger patients with asymptomatic, early stage CLL is increasing due to more frequent blood testing during routine doctor visits.
Routine genetic testing can now detect mutations and chromosomal abnormalities that impact a patient’s prognosis and therapeutic options.
